Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totaling 141,864 shares, an increase of 313.3% from the September 30th total of 34,322 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average trading volume of 60,205 shares, the days-to-cover ratio is currently 2.4 days.
Radiopharm Theranostics Trading Up 5.6%
Shares of RADX traded up $0.05 on Wednesday, reaching $0.95. The company’s stock had a trading volume of 25,068 shares, compared to its average volume of 90,457. Radiopharm Theranostics has a twelve month low of $0.90 and a twelve month high of $16.25. The firm has a fifty day moving average of $1.67 and a 200-day moving average of $3.74.
Radiopharm Theranostics (NASDAQ:RADX – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported ($0.81) EPS for the quarter. The business had revenue of $0.49 million during the quarter. As a group, research analysts predict that Radiopharm Theranostics will post -3.23 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Radiopharm Theranostics
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $11.00.
View Our Latest Report on RADX
About Radiopharm Theranostics
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer. Its approach combines tumor-targeting molecules with radioactive isotopes to create imaging agents for positron emission tomography and therapeutic candidates designed to deliver radiation directly to cancer cells.
The company is developing a pipeline of diagnostic and therapeutic radiopharmaceuticals intended to address solid tumors and other difficult-to-treat cancers.
Recommended Stories
- Five stocks we like better than Radiopharm Theranostics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Radiopharm Theranostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics and related companies with MarketBeat.com's FREE daily email newsletter.
